MBX Biosciences Reports Third Quarter 2026 Financial Results and Corporate Highlights
Globe Newswire•09/11/2026•16:01 ET
0
Key Highlights
- ➤$481.6 million cash and investments expected to fund operations into 2029
- ➤Phase 3 oPTimize trial of once-weekly canvuparatide is underway
- ➤MBX 4291 12-week MAD data remains on track for Q4 2026
- ➤Q3 R&D expenses rose to $32.0 million from $19.3 million
- ➤Q3 net loss widened to $62.4 million from $21.6 million
Expert Statements
Steve Hoerter, Chairman and Chief Executive Officer of MBX Biosciences
“The third quarter marked an important milestone for MBX with the initiation of our pivotal Phase 3 oPTimize trial of once-weekly canvuparatide, a potential best-in-class PTH replacement therapy”
Steve Hoerter, Chairman and Chief Executive Officer of MBX Biosciences
“We remain on track to report unblinded 12-week MAD Phase 1 data for MBX 4291, which is designed to deliver true once-monthly dosing and we believe has the potential to offer improved gastrointestinal tolerability.”
Steve Hoerter, Chairman and Chief Executive Officer of MBX Biosciences
“Meanwhile, we continue to advance multiple preclinical obesity programs all enabled by our clinically-validated and differentiated Precision Endocrine Peptide (PEP™) platform.”
Steve Hoerter, Chairman and Chief Executive Officer of MBX Biosciences
“With a strong balance sheet and cash runway into 2029, we believe we are well positioned to advance canvuparatide through pivotal development while continuing to invest in our growing obesity portfolio.”
Enrollment in pivotal Phase 3 oPTimize trial of once-weekly canvuparatide underway
12-week MAD (Part C, Cohort 1) data for MBX 4291, a GLP-1/GIP co-agonist prodrug for obesity designed for once-monthly dosing, on track for Q4 2026
Get started
Create a free account to read the full story.